Drug Database
AN

anti-hepatitis-B therapy (IMMUNO HBS / UMANBIG / IMMUNOHBS)

✓ Approved

Kedrion · 多克隆抗体 · 多克隆抗体

什么是 anti-hepatitis-B therapy?

anti-hepatitis-B therapy 是一种多克隆抗体,由Kedrion研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Intravenous (IV)。

药物档案

商品名IMMUNO HBS, UMANBIG, IMMUNOHBS
公司Kedrion
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intramuscular (IM) Injection, Intravenous (IV)
状态Approved

治疗适应症

anti-hepatitis-B therapy 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsHepatitis B✓ Approved

相关研究文献

PubMedGut pathogens2026-11-19

Candidate epistatic mutation clusters in occult hepatitis B virus genotype D: a critical narrative review of the evidence gap and a proposed testable framework.

Alkhulaifi Fatima S FS, Al-Qahtani Arwa A AA, Alqassim Emad E, Aljowaie Reem M RM et al.

Hepatitis B virus (HBV) genotype D is the dominant genotype across the Middle East. It forms the background against which diagnostic assays, blood-screening algorithms, and vaccination programmes operate in the region. Occult hepatitis B infection (OBI), the presence of replication-competent HBV DNA in individuals who test negative for hepatitis B surface antigen (HBsAg), remains a persistent challenge for diagnosis, for transfusion and transplant safety, and for the management of immunosuppressed patients. Individual surface-protein escape mutations are well characterised, yet they account only incompletely for the full spectrum of OBI. It is not yet established whether combinations of co-occurring surface mutations interact non-additively, that is epistatically, to influence HBsAg detectability, secretion, or replication in genotype D, whether such combinations are enriched in Middle Eastern populations, or whether they are shaped by HIV or HCV coinfection. The functional and structural data required to answer these questions are largely absent. We critically appraise the available evidence, separate established findings from extrapolation and hypothesis using an explicit grading scheme, and propose a testable bioinformatic and experimental framework to determine whether candidate epistatic clusters contribute to OBI in genotype D. We propose and apply a four-level evidence hierarchy distinguishing co-occurrence, phylogenetically corrected covariation, experimental single-versus-combination comparison, and mechanistic validation. Against this hierarchy, published data on HBsAg mutation clusters in genotype D reach Level 1-2 at most; the decisive Level 3 experiment, site-directed reconstruction of candidate clusters versus their constituent single mutants on a defined genotype D backbone, has not been performed. Genotype-D-specific and Middle-East-specific datasets adequate for cluster-level analysis are limited, direct evidence linking coinfection to selection of mutation clusters is absent, and structural inference remains constrained because recent cryo-EM structures of HBsAg subviral particles do not resolve the 'a' determinant loops at the resolution required to interpret mutation-cluster-level conformational perturbations. Epistasis is a biologically plausible, under-tested mechanism that may help explain why single mutations incompletely account for OBI. It should not be presented as an established driver. We define the sequencing, functional, structural, and clinical studies required to test the hypothesis directly, and we identify the methodological safeguards, particularly phylogenetic correction, that any such effort must adopt.

PMID 43053089
阅读全文 →
PubMedBMC infectious diseases2026-11-19

Comparative analysis of SNPs associated with COVID-19 and chronic liver disease identifies DPP9 as a candidate genetic marker for Long COVID.

da Silva Lucas Lima LL, Maya-Miles Douglas D, Maul Juliana Cardoso JC, Paulo Iolanda Raquel Ferreira IRF et al.

Long COVID is a multisystemic condition characterized by persistent symptoms after acute SARS-CoV-2 infection, whose biological mechanisms are not yet fully understood. Host genetic factors may be associated, and the sharing of genetic architecture with other chronic diseases such as viral hepatitis B and C may aid in understanding this disease. A cross-sectional study was conducted including 150 individuals stratified into two groups: (i) Long COVID and (ii) chronic viral hepatitis B and C. Eighteen single nucleotide polymorphisms (SNPs) previously associated with COVID-19 severity and inflammatory pathways were genotyped using TaqMan® real-time PCR assays. The analyses of genetic association models were performed using multivariate logistic regression adjusted for gender, self-reported skin color, and comorbidities. Mental health scales for assessing depression (Beck), anxiety (Hamilton), fatigue, and post-COVID functional scale were used both to define the syndrome and for subsequent analyses of the genotypic profile probably associated with Long COVID. Among all the SNPs analyzed, rs12610495 (A/G) in the DPP9 gene was the only variant consistently associated with Long COVID. After adjustment for sex, self-reported skin color, and hepatitis status, carriers of the G variant allele demonstrated increased odds of Long COVID under the dominant model (OR = 2.66; 95% CI: 1.08-6.57; p = 0.029) and the overdominant model (OR = 2.96; 95% CI: 1.17-7.52; p = 0.018). The association was more pronounced in women (OR = 3.30; 95% CI: 1.08-10.07). Exploratory analyses of mental and functional outcomes did not reach statistical significance, although a higher frequency of functional limitation and fatigue was observed among carriers of the G allele. This study suggests that DPP9 rs12610495 is associated with Long COVID, previously associated only with severe acute COVID, demonstrating that individuals carrying the rs12610495 G variant allele had higher odds of developing Long COVID. The inclusion of viral hepatitis as a chronic inflammatory condition for comparison contributed to the identification of shared genetic archetypal among diseases, revealing the possible role of DPP9 with Long COVID and highlighting this gene as a relevant target for future validation studies.

PMID 43052846
阅读全文 →
PubMedHepatology international2026-11-19

Longitudinal liver stiffness trajectories and dynamic prediction of liver-related events in chronic hepatitis B.

Jiang Hao H, Chen Yanlin Y, Yu Hongsheng H, Xie Biao B et al.

Serial liver stiffness measurement (LSM) captures evolving disease severity in chronic hepatitis B (CHB), but its longitudinal phenotypes and prognostic value remain uncertain. We aimed to characterize LSM trajectories and develop and externally validate joint models for individualized dynamic prediction of liver-related events (LREs). We analyzed a Beijing development cohort (n=3,927), two external-validation cohorts (n=1,987 and n=747), and a histology-characterized dataset (n=579). Latent class mixed models characterized LSM trajectories, and Bayesian joint models linked repeated LSM measurements with time-to-event outcomes to generate individualized risk estimates. Six LSM phenotypes showed marked prognostic separation, with 9-year LRE incidence ranging from 1.3 to 63.1% (p < 0.001). Despite rapid LSM decline, the moderate-baseline rapid-decline phenotype retained excess hepatocellular carcinoma (HCC) risk versus the persistent low-stable phenotype (adjusted HR 3.46, 95% CI 1.67-7.18). Each 20% increase in updated LSM was associated with LREs (adjusted HR 1.37, 95% CI 1.29-1.46), hepatic decompensation (1.55, 1.43-1.68), and HCC (1.23, 1.14-1.33). For 3-year LRE prediction, the dynamic LSM joint model achieved a mean landmark AUC of 0.833 and generally outperformed joint models based on serial PLT, APRI, and FIB-4, as well as Cox models using the most recent or baseline LSM (median ΔAUC 0.050 [IQR 0.030-0.079] and 0.100 [0.094-0.114], respectively). Adding clinical covariates increased the mean AUC to 0.859, and the final model showed good discrimination in SYSU3 and GEH-SMU (AUCs 0.854 and 0.827, respectively). Serial LSM captures clinically meaningful longitudinal heterogeneity in CHB and supports individualized, dynamically updated risk prediction.

PMID 43052628
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Receptor-Guided Targeted Protein Degradation Collapses Extracellular Vesicle-Driven Tumor-Stroma Crosstalk.

Kim Eun Hye EH, Park Byeongmin B, Kim Kyungsu K, Ryu Youngri Y et al.

Extracellular vesicles (EVs) are critical mediators of tumor-stromal communication within the tumor microenvironment (TME), where reciprocal signaling between cancer cells and cancer-associated fibroblasts (CAFs) fuels malignant progression and therapeutic resistance. Here, we report a degrader-antibody conjugate (DAC) platform, Ctx-ETAC, in which the clinically approved anti-EGFR antibody cetuximab (Ctx) delivers an engineered proteolysis-targeting chimera (PROTAC) payload, ETAC, selectively into EGFR-expressing tumor cells and activated CAFs via receptor-mediated endocytosis. ETAC integrates indomethacin as the COX-2 ligand, a VHL-recruiting peptide, and a cathepsin B (Cat-B)-cleavable azidoacetyl-RR linker; conjugation to Ctx was achieved by a two-step bioorthogonal strategy, yielding an average drug-to-antibody ratio of 4.21. The resulting Ctx-ETAC ensures biomarker-selective payload activation in both tumor cells and activated CAFs, markedly reducing EV secretion by 95.5% and thereby disrupting their crosstalk. This disruption of EV-mediated communication reprograms CAFs toward a quiescent phenotype and reshapes the non-small cell lung cancer microenvironment into an antitumor state. In a xenograft model, Ctx-ETAC achieves markedly superior tumor suppression compared with Ctx monotherapy, without systemic toxicity. These findings establish receptor-guided targeted protein degradation as a strategy to disrupt EV-driven tumor-stromal communication and provide a new framework for microenvironment-directed cancer therapy.

PMID 43053353
阅读全文 →
PubMedBMC gastroenterology2026-11-19

Predictive factors and long-term outcomes of anastomotic leakage closure in Crohn's disease: a retrospective cohort study.

Liu Wei W, Qi Weilin W, Ge Xiaolong X, Wei Ziyao Z et al.

The management of anastomotic leakage (AL) in Crohn's disease (CD) lacks standardized protocols. Identifying predictors of successful AL closure is crucial for surgeons to select the optimal treatment strategy. This study aimed to identify the predictive factors for AL closure in patients with CD and assess long-term outcomes. CD patients with AL between January 2012 and December 2022 were included in this study. Logistic regression models were used to identify the predictors of AL closure. Kaplan-Meier analysis and Cox regression models were used to evaluate long-term outcomes and risk factors for surgical recurrence. Sixty-two patients with AL from 1068 CD patients who underwent bowel surgery were included in the study, of whom 40 (64.5%) achieved AL closure through conservative treatment. Leakage from enteroenteric anastomosis was associated with significantly greater odds of AL closure (odds ratio [OR] = 5.07, p = 0.04), while preoperative use of anti-tumor necrosis factor (anti-TNF) was a risk factor (OR = 0.19, p = 0.03). Patients with AL closed had surgical recurrence rates of 2.5%, 8.3%, 14.7%, and 24.1% at 1, 2, 3, and 5 years, respectively. Maintenance anti-TNF therapy was the only factor associated with a reduced risk of surgical recurrence (hazard ratio [HR] = 0.06, p = 0.009). Conservative treatment was a viable option for AL management in CD patients. Patients with leakage from enteroenteric anastomosis and those naïve to anti-TNF therapy had higher AL closure rates. Maintenance anti-TNF therapy was associated with a lower risk of surgical recurrence.

PMID 43052741
阅读全文 →
PubMedEmerging infectious diseases2026-11-19

Rat Hepatitis E Virus and Seoul Hantavirus in Pet Rats, Germany.

Mehl Calvin C, Schilling-Loeffler Katja K, Haake Alexander F H AFH, Sehl-Ewert Julia J et al.

Pet rats represent a reservoir of multiple zoonotic pathogens. We demonstrated that pet rats, previously confirmed to be Seoul orthohantavirus-infected and involved in human infections in Germany, were concurrently infected with rat hepatitis E virus. The high degree of rat hepatitis E virus sequence identity suggests a single incursion event.

PMID 43052263
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多anti-hepatitis-B therapy